BioPharma Credit PLC USD · LSE:BPCP

BioPharma Credit PLC USD — BioPharma Credit — Investor Presentation (September 2018)

8 slides from BioPharma Credit PLC USD's investor presentation, Sep 27, 2018

  1. Slide 1: Debt Capital for the Life Sciences Industry

    Debt Capital for the Life Sciences Industry COMPANY PRESENTATION – September 2018 For additional information please email: ir@bpcruk.com or visit BioPharma Credit’s website at www.bpcruk.com

  2. Slide 2: Disclaimer

    Disclaimer THIS PRESENTATION IS BEING PROVIDED TO YOU SOLELY FOR YOUR INFORMATION. THIS PRESENTATION IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTI

  3. Slide 3: Disclaimer

    Disclaimer This presentation was prepared using the financial information available to the Company as at the date of this presentation. Except where otherwise indicated herein, the information provided in this presentation is based on matters as they exist as of the date of preparation and not as of

  4. Slide 4: Financial Highlights

    Financial Highlights ORDINARY SHARES as al 30 June 2018 Share price $1.0400 (1 December 2017: $1.0470) -0.7% NAV per Share $1.0047 GI December 2017: $1.0091) -0.4% Premium to NAV per Share 3.5% (31 December 2017: 3.8%) Shares in issue 914.3m (31 December 2017: 914.3m) Ongoing charges 1.2% (1 Decembe

  5. Slide 5: The First Eighteen Months

    The First Eighteen Months Total Raised IPO – $762m gross Placing of Ordinary Issue of C-Shares ~$1,080m gross proceeds including Shares – $154m – $163m gross proceeds $339m of seed gross proceeds proceeds assets ($740m in cash) March 2017 Q2-2017 Q3-2017 Q4-2017 Q1-2018 Q2-2018 Q3-2018 $150m loan in

  6. Slide 6: The First Eighteen Months

    The First Eighteen Months BioPharma Credit is currently substantially invested (millions) BPCR Porfolio Composition (pre Amicus transaction) $1,200 $23 ~ $239m or 70% of seed assets $1,000 $125 RPS (RPS + BP-III) have amortized since IPO $150 BioPharma III $800 Cash $194 Despite the $239m in $600 Te

  7. Slide 7: Summary of Assets

    Summary of Assets Seed Assets Post-IPO Investments Borrower: ROYALTY PHARMA Pharmakon Advisors, LP “YRPS Biopharma Investments LP -~ . Investment: (RPS) (BioPharma Il) wIESARO : 46% Limited invesiment Type Seared oan Patnerstip terest. S@Mee loan ristol-Myers Squibb Priority Royalty Stream ec Lexico

  8. Slide 8: $150m senior secured corporate loan to Amicus Therapeutics

    $150m senior secured corporate loan to Amicus Therapeutics Key terms of loan  Description: Amicus Therapeutics, Inc. (FOLD) is a biopharmaceutical  Size of facility: $150m to be funded in one tranche company focused on in-licensing and developing product candidates for  Funding fee: 2% the treatm

BioPharma Credit — Investor Presentation (September 2018) on 6ix